Search

Displaying results 9631 - 9640 of 10000 in total
  1. Drug

    Socazolimab

    go.drugbank.com/drugs/DB18845
    Investigational

    Socazolimab is under investigation in clinical trial NCT04878016 (A Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-pd-l1 Antibody) in Patients With ES-SCLC).

  2. Drug

    Efruxifermin

    go.drugbank.com/drugs/DB19012
    Investigational

    Efruxifermin is under investigation in clinical trial NCT06215716 (A Study Evaluating Efruxifermin in Subjects With Non-cirrhotic Nonalcoholic Steatohepatitis (Nash)/metabolic Dysfunction-associated Steatohepatitis

  3. Drug

    XT-150

    go.drugbank.com/drugs/DB21756
    Investigational

    XT-150 is a locally injectable non-viral therapy expressing IL-10v, a proprietary modified variant of IL-10.[L52125] It is being developed by Xalud Therapeutics.

    Synonyms: non-viral human interleukin-10 (IL-10) variant (IL-10var) encoding plasmid deoxyribonucleic acid (pDNA)
  4. Drug

    Luxdegalutamide

    go.drugbank.com/drugs/DB22370
    Investigational

    JSB462 is under investigation in clinical trial NCT07047118 (A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer

  5. Drug

    Izalontamab brengitecan

    go.drugbank.com/drugs/DB22567
    Investigational

    Izalontamab brengitecan is under investigation in clinical trial NCT07054567 (A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial

  6. Drug

    OAV201

    go.drugbank.com/drugs/DB17842
    Experimental

    It was first developed by Novartis and investigated for the treatment of Rett syndrome, but further investigation in clinical trials was halted.[L46661] … OAV201 is a non-replicating, recombinant adeno-associated virus serotype 9 (AAV9) containing the human Methyl CpG Binding Protein 2B (MECP2B) cDNA under the control of a segment of the murine MECP2 promoter

  7. Drug

    Englumafusp alfa

    go.drugbank.com/drugs/DB19341
    Investigational

    Englumafusp alfa is under investigation in clinical trial NCT04077723 (A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab … and in Combination With Glofitamab Following a Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/refractory B-cell Non-hodgkin's Lymphoma).

  8. Drug

    tgAAVCF

    go.drugbank.com/drugs/DB17849
    Investigational

    It is being investigated for the treatment of cystic fibrosis.[A259821, A259826] … tgAAVCF is an adeno-associated virus (AAV) vector encoding the human cystic fibrosis transmembrane conductance regulator protein (CFTR) cDNA.

  9. Drug

    Fluciclatide

    go.drugbank.com/drugs/DB14842
    Investigational

    The conditions targeted by [18F]Fluciclatide in these studies include high-grade glioma, lung cancer, and kidney neoplasms … Fluciclatide, an investigational radiotracer intended for PET imaging, was under investigation in clinical trials NCT00565721 and NCT01961583 to evaluate its ability to detect tumors and angiogenesis.

  10. Drug

    MVC-COV1901

    go.drugbank.com/drugs/DB15854
    Investigational

    As of September 2020, the vaccine candidate is in Phase 1 clinical trials to assess its safety and immunogenicity (NCT04487210). … MVC-COV1901 is a vaccine candidate developed and commercialized by Medigen Vaccine Biologics Corporation. The vaccine candidate contains a perfusion form of the SARS-Cov2 recombinant spike protein.